News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Merck KGaA MS Pill Cladribine Rejected by European Medicines Evaluation Agency
September 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, Sept 24 (Reuters) - European regulators dealt Merck KGaA (MRCG.DE) a major blow by recommending against its biggest pipeline drug, multiple sclerosis (MS) pill cladribine, adding to a string of setbacks at the company's drugs unit.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Regulatory
Europe
MORE ON THIS TOPIC
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
September 8, 2025
·
2 min read
·
Annalee Armstrong
Lung cancer
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions
September 8, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’
September 5, 2025
·
3 min read
·
Dan Samorodnitsky
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
